Polyclonal Anti-Malondialdehyde Antiserum

Malondialdehyde (MDA) is a natural product formed in all mammalian cells either as a product of lipid peroxidation, or as a by-product of prostaglandin and thromboxane biosynthesis.  Although MDA can be broken down by aldehyde dehydrogenases, its production is accelerated by oxidative stress and when its concentrations reach critical levels, it may escape this detoxification process.  It is highly reactive and known to bind covalently with primary amino groups of proteins, phospholipids, or DNA, but has no known physiological function.  This covalence modification of cellular molecules may cause structural modifications, which results in dysfunction or inactivation. MDA is toxic and has been implicated in aging, mutagenesis, carcinogenesis, radiation damage and a number of other pathological processes. 

MDA is known to increase in tissue and plasma samples with age.  It is known to bind to low density lipoprotein resulting in the recognition of the MDA-modified LDL by scavenger receptors on macrophages.  It has also been shown to be present in renal glomerular lesions in diabetics, implicating oxidative stress as being involved in the pathogenesis of diabetic nephopathy.  MDA has been shown to be increased in the brains of aged individuals and further increased in Alzheimer brains.

A goat antiserum to MDA is currently available. This antiserum has been shown to be immunoreactive with MDA-modified bovine serum albumin (BSA) by ELISA.  Western blot analysis show sthe antibody is capable of detecting HNE-modied proteins.  This antibody should be a valuable tool for scientists working to understand the role of MDA in the pathogenesis of various diseases.

 MDA-modified BSA (Cat no. HMP039H) which can be used as a positive control or to neutralize immunoreactivity is also available.

Manufacturing Reference: 

Lung, C.C, et al. J. Immunol. Meth. 128: 127-132, 1990.